BACKGROUND: To identify the value of von Willebrand factor (vWF) as a clinical marker in colorectal carcinoma (CRC). METHODS: Plasma levels of vWF were measured in 79 patients with UICC Stage I-IV CRC at time of operation and correlated with TNM categories, levels of the carcinoembryonic antigen (CEA), blood groups (BG) and 19 controls (CO). CO included cancer-free patients without bacterial or viral infections. For tissue analysis paraffin embedded tumour and mucosa sections of operation specimens were stained immunohistochemically for vWF and compared to vWF plasma levels as well as to TNM categories. RESULTS: VWF plasma levels in CRC patients were significantly dependent on blood groups (p=0.012) and elevated compared to the normal ranges as well as to controls (BG 0: p=0.668, BG A/AB/B: p=0.020). CRC-Patients over 60 years of age presented with significantly higher vWF levels than patients below 60 years (BG 0: p=0.005; BG A/AB/B: p=0.035). There was no correlation of vWF plasma levels and UICC stages in CRC. Patients with elevated vWF plasma levels also presented with elevated CEA levels, but significance was missing (p=0.080). VWF concentration within the tumour tissue was independent of concentration within normal mucosa, blood groups, histopathological characteristics and did not correlate with plasma vWF levels. CONCLUSION: VWF plasma levels are elevated in CRC patients, but not in a stage dependent manner. Besides the tumour at least blood groups and age mainly influence plasma vWF levels. In our opinion vWF as a routinely used clinical marker in CRC cannot be recommended.
BACKGROUND: To identify the value of von Willebrand factor (vWF) as a clinical marker in colorectal carcinoma (CRC). METHODS: Plasma levels of vWF were measured in 79 patients with UICC Stage I-IV CRC at time of operation and correlated with TNM categories, levels of the carcinoembryonic antigen (CEA), blood groups (BG) and 19 controls (CO). CO included cancer-free patients without bacterial or viral infections. For tissue analysis paraffin embedded tumour and mucosa sections of operation specimens were stained immunohistochemically for vWF and compared to vWF plasma levels as well as to TNM categories. RESULTS:VWF plasma levels in CRC patients were significantly dependent on blood groups (p=0.012) and elevated compared to the normal ranges as well as to controls (BG 0: p=0.668, BG A/AB/B: p=0.020). CRC-Patients over 60 years of age presented with significantly higher vWF levels than patients below 60 years (BG 0: p=0.005; BG A/AB/B: p=0.035). There was no correlation of vWF plasma levels and UICC stages in CRC. Patients with elevated vWF plasma levels also presented with elevated CEA levels, but significance was missing (p=0.080). VWF concentration within the tumour tissue was independent of concentration within normal mucosa, blood groups, histopathological characteristics and did not correlate with plasma vWF levels. CONCLUSION:VWF plasma levels are elevated in CRC patients, but not in a stage dependent manner. Besides the tumour at least blood groups and age mainly influence plasma vWF levels. In our opinion vWF as a routinely used clinical marker in CRC cannot be recommended.
Entities:
Keywords:
blood group; colorectal cancer; von Willebrand factor
Authors: Clara Lubeseder-Martellato; Eric Guenzi; Anita Jörg; Kristin Töpolt; Elisabeth Naschberger; Elisabeth Kremmer; Christian Zietz; Erwin Tschachler; Peter Hutzler; Martin Schwemmle; Kathrin Matzen; Thomas Grimm; Barbara Ensoli; Michael Stürzl Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: E Guenzi; K Töpolt; E Cornali; C Lubeseder-Martellato; A Jörg; K Matzen; C Zietz; E Kremmer; F Nappi; M Schwemmle; C Hohenadl; G Barillari; E Tschachler; P Monini; B Ensoli; M Stürzl Journal: EMBO J Date: 2001-10-15 Impact factor: 11.598
Authors: M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan Journal: Eur J Cancer Date: 2007-05-18 Impact factor: 9.162
Authors: Josep Tabernero; Heinz-Josef Lenz; Salvatore Siena; Alberto Sobrero; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Takayuki Yoshino; Richard M Goldberg; Daniel J Sargent; Andrea Wagner; Dirk Laurent; Michael Teufel; Michael Jeffers; Axel Grothey; Eric Van Cutsem Journal: Lancet Oncol Date: 2015-07-13 Impact factor: 41.316
Authors: Lin Zhang; Juan Ye; Qiuyun Luo; Miaohuan Kuang; Minjie Mao; Shuqin Dai; Xueping Wang Journal: Cancer Manag Res Date: 2020-07-03 Impact factor: 3.989
Authors: Roland S Croner; Michael Stürzl; Tilman T Rau; Gergana Metodieva; Carol I Geppert; Elisabeth Naschberger; Berthold Lausen; Metodi V Metodiev Journal: Int J Cancer Date: 2014-05-12 Impact factor: 7.396